by John Conrad | Jun 14, 2024 | NewsBrief
Congratulations to iBIO member Tempus AI and its founder, Eric Lefkofsky, on their remarkable achievement! We are thrilled to announce that Tempus AI, a trailblazing precision-medicine startup, is set to make its highly anticipated debut on the stock market this...
by John Conrad | Jun 13, 2024 | NewsBrief
Inflammatory Bowel Disease (IBD) affects millions of people worldwide, causing chronic inflammation in the digestive tract and leading to debilitating symptoms. Current therapies often fail to provide adequate relief for many patients, highlighting the urgent need for...
by John Conrad | Jun 13, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based pharmaceutical company, has been named the second fastest growing company on Crain’s Fast 50 list. The company recorded an impressive 13,294.6% growth rate, with over $230 million in revenue and a total of 90 employees,...
by John Conrad | Jun 12, 2024 | NewsBrief
Scientists from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago have discovered a way to regenerate damaged heart muscle cells in mice, a development which may provide a new avenue for treating congenital heart...
by John Conrad | Jun 12, 2024 | NewsBrief
GE HealthCare continues to make significant strides in expanding access to precision care tools and encouraging the adoption of personalized medicine worldwide. At the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, the company...
by John Conrad | Jun 10, 2024 | NewsBrief
In a significant development for patients with vanishing white matter (VWM) disease, AbbVie and Alphabet’s Calico announced on Friday that their investigational eIF2B activator, fosigotifator, has been selected to participate in the FDA’s new Support for...
